Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 3

Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

NCT05305794 · tracked via the Priya Life Science France tracker
Phase
Phase 3
Started
2022-07-12
Last updated
2026-09-29

Condition(s) studied

Double Diabetes

Investigational drug(s) / intervention(s)

Insulin + semaglutide treatment →Usual insulin treatmentBiological check-up →

Insulin + semaglutide treatment: Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)

Usual insulin treatment: Usual insulin treatment

Biological check-up: at D0, D90 and D180

Study summary

Between 16% and 22% of type 1 diabetic patients present a clinical and biological profile of insulin resistance favored by a family history of type 2 diabetes or metabolic syndrome. They constitute a group of patients with "double diabetes" since they have both true type 1 diabetes and inherited insulin resistance, typical of type 2 diabetes.

For several years, GLP1 agonists have been successfully used in the treatment of type 2 diabetes, leading to very significant improvements in glycemic control and weight loss.

Because of the insulin-sensitizing power of GLP1 agonists, the investigators hypothesize that they could reduce insulin resistance in patients with "double diabetes" and thus improve their glycemic control.

The investigators propose to use in this study semaglutide, the most recent and most potent GLP1 agonist (superiority demonstrated compared to exenatide LP and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide administered daily).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Person who has given written consent * Patient over 18 years of age * Patient with type 1 diabetes confirmed by a C-peptide below laboratory standards * Age at diagnosis \< 35 years * Treated with optimized insulin therapy (multi-injections or pump) for at least 1 year, having received specific therapeutic education on insulin dose adaptation. * BMI (weight/height2) ≥ 27 Kg/m². * At least one of the following criteria: * Family history of type 2 diabetes (parents, grandparents, uncles, aunts, brothers and sisters) * Family history of obesity (BMI\>30 Kg/m2) (parents, grandparents, uncles, aunts, siblings) * Triglycerides \> 1.50g/l (1.7mmol/l) * HDL\< 0.5 g/l (1.29 mmol/l) in women, HDL\<0.4 g/l (1.03 mmol/l) in men * HbA1c ≥ 7.5% and \< 12% in the 3 months preceding inclusion * Having continuous glucose monitoring by a CGM (Holter Glucose Monitoring) system: Guardian, Dexcom or Free Style Libre * For women of childbearing age: using an effective method of contraception until 2 months after the end of treatment. Effective contraception includes: hormonal contraception, intrauterine device, bilateral tubal occlusion, vasectomy and sexual abstinence Exclusion Criteria: * person not affiliated to national health insurance * Pregnant, parturient or breastfeeding woman * HbA1c ≥12% in the 3 months preceding inclusion. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy, confirmed by a fundus examination performed in the 6 months preceding the selection * Person under a measure of legal protection (curatorship, guardianship) * Renal insufficiency (GFR\<30 ml/mn) * Hepatic insufficiency (INR\> 1.5) * BMI \>40 kg/m². * History of bariatric surgery * History of pancreatitis * Allergy to the active substance or to one of the excipients of OZEMPIC®. * Patients who have received GLP-1 agonist therapy or who received such therapy within the year prior to enrollment * Patients who have received oral antidiabetic therapy within the month prior to enrollment

Primary outcome measure(s)

  • Percentage of time spent within glycemic target range (0.70-1.80 g/l) — Change from baseline at Day 180

Trial sites (1)

FacilityCityRegionStatus
Chu Dijon Bourgogne Dijon France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05305794 on ClinicalTrials.gov ↗ ← All trials in France